I agree with that. I was actually very excited to come across RQL, given that they will clearly have a cracker FY11 result and earnings will likely grow strongly. However, when I "normalised" the businesses equity (I've worked back from pre-listing accounts in FY06 and ignored the accounting adjustments for acquisitions to get a good read of what capital (debt and equity) has been employed in the business over its life. For FY11 I have equity of $73 million and NPAT of $8.26 million (it is forecast to be $11.8 million, but only because of tax losses, so I have normalised NPAT). This gives a ROE of 11%. I have the ROE picking up in FY12 to 15% and in FY13 to 16%. Therefore, I have valued the business using a long run ROE of 15%. Assuming I was a return of 12%pa to compensate for the risk, and assuming all earnings are paid out as dividend, I'd pay 1.25 (15/12) time equity. With normalised equity of $73.4 in FY11, that gives me a value of $0.37 - slightly higher if they retain earnings - about - up to about $0.45 if they retain all earnings.
Unfortunately it has taken me significant time and research to nut this out, so I thought it appropriate to post so others can benefit / discuss my results.
- Forums
- ASX - By Stock
- RQL
- valuation?
valuation?, page-6
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RQL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online